Abstract
The nephrotoxic potential of iphosphamide was evaluated in a retrospective analysis of all children receiving the drug at The Hospital for Sick Children in Toronto. The 25 children exhibiting nephrotoxicity did not receive more cycles or higher doses per square metre than the 78 with normal renal function. Similarly, the two groups received comparable doses and number of cycles of sodium 2-mercaptoethanesulphonate, and had similar rates of exposure to nephrotoxic drugs (except forcis-platinum). Children exhibiting nephrotoxicity were significantly younger (78.1±64.1 months) than those having normal kidney function (103.8±66.6 months) (P<0.05). Children exhibiting nephrotoxicity were more likely to have receivedcis-platinum prior to the iphosphamide (10/25, 40%) than those with normal renal function (14/73, 18%) (P<0.05). Nephrotoxicity was associated with a significant effect on growth. Careful follow-up of renal function should take place in children receiving iphosphamide, with special attention paid to children younger than 5 years of age and those who have receivedcis-platinum.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jurgens H, Treuner J, Winkler K, Gobel U (1989) Iphosphamide in pediatric malignancies. Semin Oncol 16:46–50
Kushner BH, Cheung NKV (1990) Cyclophosphamide versus ifosfamide in paediatric oncology. Lancet 330:253–254
Goren MP, Wright RK, Horowitz ME, Pratt CB (1987) Ifosfamide-induced subclinical tubular nephrotoxicity despite MENSA. Cancer Treat Rep 71:127–130
Davies SM, Pearson ADJ, Craft AW (1989) Toxicity of high-dose ifosfamide in children. Cancer Chemother Pharmacol 24:S8-S10
Skinner R, Pearson ADJ, Price L, Cunningham R, Craft AW (1989) Hypophosphataemic rickets after ifosfamide treatment in children. BMJ 298:1560–1561
Moncrieff M, Foot A (1989) Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 23:121–122
Abelson WH, Smith RG (1987) The residents handbook of pediatrics, 1th edn. The Hospital for Sick Children, Toronto, Canada.
Goodman A, and Gilman LS (1990) The pharmacological basis of therapeutics. Pergamon, New York, p 1250
Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH (1987) Potentiation of iphosphamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by priorcis-diaminedichloroplatinum (II) therapy. Cancer Res 47:1457–1460
Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW (1990) Nephrotoxicity after iphosphamide. Arch Dis Child 65:732–738
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shore, R., Greenberg, M., Geary, D. et al. Iphosphamide-induced nephrotoxicity in children. Pediatr Nephrol 6, 162–165 (1992). https://doi.org/10.1007/BF00866300
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00866300